메뉴 건너뛰기




Volumn 9, Issue 3, 2013, Pages 183-194

Creative trial design in RA: Optimizing patient outcomes

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL MARKER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ERLOTINIB; METHOTREXATE; PEMETREXED; TOCILIZUMAB;

EID: 84874645048     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.5     Document Type: Review
Times cited : (14)

References (90)
  • 1
    • 0035883897 scopus 로고    scopus 로고
    • Rheumatoid arthritis
    • Lee, D. M. & Weinblatt, M. E. Rheumatoid arthritis. Lancet 358, 903-911 (2001).
    • (2001) Lancet , vol.358 , pp. 903-911
    • Lee, D.M.1    Weinblatt, M.E.2
  • 2
    • 84958107344 scopus 로고
    • The effect of a hormone of the adrenal cortex (17-hydroxy-11- dehydrocorticosterone; Compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis
    • Hench, P. S. et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc. Staff Meet. Mayo Clin. 24, 181-197 (1949).
    • (1949) Proc. Staff Meet. Mayo Clin , vol.24 , pp. 181-197
    • Hench, P.S.1
  • 3
    • 57149112328 scopus 로고    scopus 로고
    • Issues in the design of new clinical trials for rheumatoid arthritis therapeutics
    • Schwieterman, W. D. Issues in the design of new clinical trials for rheumatoid arthritis therapeutics. Nat. Clin. Pract. Rheumatol. 4, 641-648 (2008).
    • (2008) Nat. Clin. Pract. Rheumatol , vol.4 , pp. 641-648
    • Schwieterman, W.D.1
  • 4
    • 9244247260 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
    • O'Dell, J. R. et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334, 1287-1291 (1996).
    • (1996) N. Engl. J. Med , vol.334 , pp. 1287-1291
    • O'Dell, J.R.1
  • 5
    • 0028572390 scopus 로고
    • Combination of methotrexate and sulphasalazine vs methotrexate alone: A randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy
    • Haagsma, C. J. et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br. J. Rheumatol. 33, 1049-1055 (1994).
    • (1994) Br. J. Rheumatol , vol.33 , pp. 1049-1055
    • Haagsma, C.J.1
  • 6
    • 0032957015 scopus 로고    scopus 로고
    • Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
    • Dougados, M. et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann. Rheum. Dis. 58, 220-225 (1999).
    • (1999) Ann. Rheum. Dis , vol.58 , pp. 220-225
    • Dougados, M.1
  • 7
    • 0030751946 scopus 로고    scopus 로고
    • Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
    • Boers, M. et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350, 309-318 (1997).
    • (1997) Lancet , vol.350 , pp. 309-318
    • Boers, M.1
  • 8
    • 0033535754 scopus 로고    scopus 로고
    • Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial
    • Mottonen, T. et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353, 1568-1573 (1999).
    • (1999) FIN-RACo Trial Group. Lancet , vol.353 , pp. 1568-1573
    • Mottonen, T.1
  • 9
    • 77950307115 scopus 로고    scopus 로고
    • Treating rheumatoid arthritis to target: Recommendations of an international task force
    • Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631-637 (2010).
    • (2010) Ann. Rheum. Dis , vol.69 , pp. 631-637
    • Smolen, J.S.1
  • 10
    • 3242677099 scopus 로고    scopus 로고
    • Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial
    • Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263-269 (2004).
    • (2004) Lancet , vol.364 , pp. 263-269
    • Grigor, C.1
  • 11
    • 27744514865 scopus 로고    scopus 로고
    • Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
    • Goekoop-Ruiterman, Y. P. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52, 3381-3390 (2005).
    • (2005) Arthritis Rheum , vol.52 , pp. 3381-3390
    • Goekoop-Ruiterman, Y.P.1
  • 12
    • 0033524159 scopus 로고    scopus 로고
    • Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial ATTRACT Study Group
    • Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932-1939 (1999).
    • (1999) Lancet , vol.354 , pp. 1932-1939
    • Maini, R.1
  • 13
    • 0033574147 scopus 로고    scopus 로고
    • Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
    • Moreland, L. W. et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130, 478-486 (1999).
    • (1999) Ann. Intern. Med , vol.130 , pp. 478-486
    • Moreland, L.W.1
  • 14
    • 0033611472 scopus 로고    scopus 로고
    • A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
    • Weinblatt, M. E. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253-259 (1999).
    • (1999) N. Engl. J. Med , vol.340 , pp. 253-259
    • Weinblatt, M.E.1
  • 15
    • 0037231533 scopus 로고    scopus 로고
    • Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
    • Weinblatt, M. E. et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 35-45 (2003).
    • (2003) Arthritis Rheum , vol.48 , pp. 35-45
    • Weinblatt, M.E.1
  • 16
    • 33746961890 scopus 로고    scopus 로고
    • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    • Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793-2806 (2006).
    • (2006) Arthritis Rheum , vol.54 , pp. 2793-2806
    • Cohen, S.B.1
  • 17
    • 24944498854 scopus 로고    scopus 로고
    • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
    • Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114-1123 (2005).
    • (2005) N. Engl. J. Med , vol.353 , pp. 1114-1123
    • Genovese, M.C.1
  • 18
    • 52149099504 scopus 로고    scopus 로고
    • IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial
    • Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516-1523 (2008).
    • (2008) Ann. Rheum. Dis , vol.67 , pp. 1516-1523
    • Emery, P.1
  • 19
    • 0014115513 scopus 로고
    • Explanatory and pragmatic attitudes in therapeutical trials
    • Schwartz, D. & Lellouch, J. Explanatory and pragmatic attitudes in therapeutical trials. J. Chronic Dis. 20, 637-648 (1967).
    • (1967) J. Chronic Dis , vol.20 , pp. 637-648
    • Schwartz, D.1    Lellouch, J.2
  • 20
    • 0023185342 scopus 로고
    • Equipoise and the ethics of clinical research
    • Freedman, B. Equipoise and the ethics of clinical research. N. Engl. J. Med. 317, 141-145 (1987).
    • (1987) N. Engl. J. Med , vol.317 , pp. 141-145
    • Freedman, B.1
  • 21
    • 2442642919 scopus 로고    scopus 로고
    • Appropriate and effective management of rheumatoid arthritis
    • Breedveld, F. C. & Kalden, J. R. Appropriate and effective management of rheumatoid arthritis. Ann. Rheum. Dis. 63, 627-633 (2004).
    • (2004) Ann. Rheum. Dis , vol.63 , pp. 627-633
    • Breedveld, F.C.1    Kalden, J.R.2
  • 22
    • 33847628013 scopus 로고    scopus 로고
    • Early rheumatoid arthritis: Strategies for prevention and management
    • Combe, B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract. Res. Clin. Rheumatol. 21, 27-42 (2007).
    • (2007) Best Pract. Res. Clin. Rheumatol , vol.21 , pp. 27-42
    • Combe, B.1
  • 24
    • 63649136121 scopus 로고    scopus 로고
    • Explanatory and pragmatic attitudes in therapeutical trials
    • Schwartz, D. & Lellouch, J. Explanatory and pragmatic attitudes in therapeutical trials. J. Clin. Epidemiol. 62, 499-505 (2009).
    • (2009) J. Clin. Epidemiol , vol.62 , pp. 499-505
    • Schwartz, D.1    Lellouch, J.2
  • 25
    • 77953696525 scopus 로고    scopus 로고
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    • Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964-975 (2010).
    • (2010) Ann. Rheum. Dis , vol.69 , pp. 964-975
    • Smolen, J.S.1
  • 26
    • 77953718691 scopus 로고    scopus 로고
    • Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
    • Knevel, R. et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 69, 987-994 (2010).
    • (2010) Ann. Rheum. Dis , vol.69 , pp. 987-994
    • Knevel, R.1
  • 27
    • 84874658243 scopus 로고    scopus 로고
    • The CONSORT Group. The CONSORT statement [online] 2013
    • The CONSORT Group. The CONSORT statement [online], http://www.consort- statement.org/consort-statement/(2013).
  • 28
    • 57349108691 scopus 로고    scopus 로고
    • Improving the reporting of pragmatic trials: An extension of the CONSORT statement
    • Zwarenstein, M. et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 337, a2390 (2008).
    • (2008) BMJ , vol.337
    • Zwarenstein, M.1
  • 31
    • 0023239521 scopus 로고
    • Effect of sulphasalazine on the radiological progression of rheumatoid arthritis
    • Pullar, T., Hunter, J. A. & Capell, H. A. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann. Rheum. Dis. 46, 398-402 (1987).
    • (1987) Ann. Rheum. Dis , vol.46 , pp. 398-402
    • Pullar, T.1    Hunter, J.A.2    Capell, H.A.3
  • 32
    • 0020503084 scopus 로고
    • Sulphasalazine in rheumatoid arthritis: A double blind comparison of sulphasalazine with placebo and sodium aurothiomalate
    • Pullar, T., Hunter, J. A. & Capell, H. A. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br. Med. J. (Clin. Res. Ed.) 287, 1102-1104 (1983).
    • (1983) Br. Med. J. (Clin. Res. Ed) , vol.287 , pp. 1102-1104
    • Pullar, T.1    Hunter, J.A.2    Capell, H.A.3
  • 33
    • 0030066368 scopus 로고    scopus 로고
    • Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis
    • ten Wolde, S. et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347, 347-352 (1996).
    • (1996) Lancet , vol.347 , pp. 347-352
    • Ten Wolde, S.1
  • 34
    • 77953706155 scopus 로고    scopus 로고
    • Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
    • Gaujoux-Viala, C. et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 69, 1004-1009 (2010).
    • (2010) Ann. Rheum. Dis , vol.69 , pp. 1004-1009
    • Gaujoux-Viala, C.1
  • 35
    • 38749141455 scopus 로고    scopus 로고
    • Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis
    • Donahue, K. E. et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann. Intern. Med. 148, 124-134 (2008).
    • (2008) Ann. Intern. Med , vol.148 , pp. 124-134
    • Donahue, K.E.1
  • 36
    • 0028143212 scopus 로고
    • Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
    • Elliott, M. J. et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125-1127 (1994).
    • (1994) Lancet , vol.344 , pp. 1125-1127
    • Elliott, M.J.1
  • 37
    • 10744223002 scopus 로고    scopus 로고
    • Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial
    • Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675-681 (2004).
    • (2004) Lancet , vol.363 , pp. 675-681
    • Klareskog, L.1
  • 38
    • 31044442965 scopus 로고    scopus 로고
    • The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
    • Breedveld, F. C. et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26-37 (2006).
    • (2006) Arthritis Rheum , vol.54 , pp. 26-37
    • Breedveld, F.C.1
  • 39
    • 77953694972 scopus 로고    scopus 로고
    • Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of RA
    • Nam, J. L. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. 69, 976-986 (2010).
    • (2010) Ann. Rheum. Dis , vol.69 , pp. 976-986
    • Nam, J.L.1
  • 40
    • 0022627532 scopus 로고
    • Rheumatoid arthritis: Treatment which controls the Creactive protein and erythrocyte sedimentation rate reduces radiological progression
    • Dawes, P. T. et al. Rheumatoid arthritis: treatment which controls the Creactive protein and erythrocyte sedimentation rate reduces radiological progression. Br. J. Rheumatol. 25, 44-49 (1986).
    • (1986) Br. J. Rheumatol , vol.25 , pp. 44-49
    • Dawes, P.T.1
  • 41
    • 0028211156 scopus 로고
    • Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants
    • van Leeuwen, M. A. et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J. Rheumatol. 21, 425-429 (1994).
    • (1994) J. Rheumatol , vol.21 , pp. 425-429
    • Van Leeuwen, M.A.1
  • 42
    • 0033501902 scopus 로고    scopus 로고
    • Long-term course and outcome of functional capacity in rheumatoid arthritis: The effect of disease activity and radiologic damage over time
    • Drossaers-Bakker, K. W. et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 42, 1854-1860 (1999).
    • (1999) Arthritis Rheum , vol.42 , pp. 1854-1860
    • Drossaers-Bakker, K.W.1
  • 43
    • 3142771252 scopus 로고    scopus 로고
    • The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysis
    • Welsing, P. M. et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum. 50, 2082-2093 (2004).
    • (2004) Arthritis Rheum , vol.50 , pp. 2082-2093
    • Welsing, P.M.1
  • 44
    • 33749319744 scopus 로고    scopus 로고
    • Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components
    • Aletaha, D., Smolen, J. & Ward, M. M. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum. 54, 2784-2792 (2006).
    • (2006) Arthritis Rheum , vol.54 , pp. 2784-2792
    • Aletaha, D.1    Smolen, J.2    Ward, M.M.3
  • 45
    • 3042649468 scopus 로고    scopus 로고
    • Radiography as primary outcome in rheumatoid arthritis: Acceptable sample sizes for trials with 3 months' follow up
    • Bruynesteyn, K., Landewe, R., van der Linden, S. & van der Heijde, D. Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up. Ann. Rheum. Dis. 63, 1413-1418 (2004).
    • (2004) Ann. Rheum. Dis , vol.63 , pp. 1413-1418
    • Bruynesteyn, K.1    Landewe, R.2    Van Der Linden, S.3    Van Der Heijde, D.4
  • 48
    • 73449087363 scopus 로고    scopus 로고
    • A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals
    • Boers, M. A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals. Ann. Rheum. Dis. 69, 4-6 (2010).
    • (2010) Ann. Rheum. Dis , vol.69 , pp. 4-6
    • Boers, M.1
  • 49
    • 55849112632 scopus 로고    scopus 로고
    • Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    • Keystone, E. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319-3329 (2008).
    • (2008) Arthritis Rheum , vol.58 , pp. 3319-3329
    • Keystone, E.1
  • 50
    • 84857697133 scopus 로고    scopus 로고
    • Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: A randomized trial
    • Bakker, M. F. et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 156, 329-339 (2012).
    • (2012) Ann. Intern. Med , vol.156 , pp. 329-339
    • Bakker, M.F.1
  • 51
    • 68049124945 scopus 로고    scopus 로고
    • Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
    • van Vollenhoven, R. F. et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374, 459-466 (2009).
    • (2009) Lancet , vol.374 , pp. 459-466
    • Van Vollenhoven, R.F.1
  • 52
    • 85027919018 scopus 로고    scopus 로고
    • Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
    • Kavanaugh, A. et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann. Rheum. Dis. 72, 64-71 (2013).
    • (2013) Ann. Rheum. Dis , vol.72 , pp. 64-71
    • Kavanaugh, A.1
  • 53
    • 84857410587 scopus 로고    scopus 로고
    • Lack of head-to-head trials and fair control arms: Randomized controlled trials of biologic treatment for rheumatoid arthritis
    • Estellat, C. & Ravaud, P. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch. Intern. Med. 172, 237-244 (2012).
    • (2012) Arch. Intern. Med , vol.172 , pp. 237-244
    • Estellat, C.1    Ravaud, P.2
  • 54
    • 78651383189 scopus 로고    scopus 로고
    • Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA
    • Smolen, J. S. et al. Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. Curr. Med. Res. Opin. 27, 315-325 (2011).
    • (2011) Curr. Med. Res. Opin , vol.27 , pp. 315-325
    • Smolen, J.S.1
  • 55
    • 84870514601 scopus 로고    scopus 로고
    • Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial [abstract LB0003]
    • Gabay, C. et al. Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial [abstract LB0003]. Ann. Rheum. Dis. 71 (Suppl. 3), 152 (2012).
    • (2012) Ann. Rheum. Dis , vol.71 , Issue.SUPPL. 3 , pp. 152
    • Gabay, C.1
  • 56
    • 84867071979 scopus 로고    scopus 로고
    • Abatacept SC versus adalimumab on background methotrexate in RA: One year results from the AMPLE study [abstract OP0022]
    • Schiff, M. et al. Abatacept SC versus adalimumab on background methotrexate in RA: one year results from the AMPLE study [abstract OP0022] Ann. Rheum. Dis. 71 (Suppl. 3), 60 (2012).
    • (2012) Ann. Rheum. Dis , vol.71 , Issue.SUPPL. 3 , pp. 60
    • Schiff, M.1
  • 57
    • 33845508231 scopus 로고    scopus 로고
    • Making sense of noninferiority: A clinical and statistical perspective on its application to cardiovascular clinical trials
    • Kaul, S. & Diamond, G. A. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials. Prog. Cardiovasc. Dis. 49, 284-299 (2007).
    • (2007) Prog. Cardiovasc. Dis , vol.49 , pp. 284-299
    • Kaul, S.1    Diamond, G.A.2
  • 58
    • 38449111304 scopus 로고    scopus 로고
    • Trend toward noninferiority trials may mean more difficult interpretation of trial results
    • Tuma, R. S. Trend toward noninferiority trials may mean more difficult interpretation of trial results. J. Natl Cancer Inst. 99, 1746-1748 (2007).
    • (2007) J. Natl Cancer Inst , vol.99 , pp. 1746-1748
    • Tuma, R.S.1
  • 59
    • 80052226713 scopus 로고    scopus 로고
    • Gain in popularity of noninferiority trial design: Caveat lector
    • Vermeulen, L. Gain in popularity of noninferiority trial design: caveat lector. Pharmacotherapy 31, 831-832 (2011).
    • (2011) Pharmacotherapy , vol.31 , pp. 831-832
    • Vermeulen, L.1
  • 60
    • 33845880693 scopus 로고    scopus 로고
    • Non-inferiority trials in oncology: Arbitrary limits, infeasible sample sizes and uninformative data analysis. Is there another way?
    • Carroll, K. J. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. Is there another way? Pharm. Stat. 5, 283-293 (2006).
    • (2006) Pharm. Stat , vol.5 , pp. 283-293
    • Carroll, K.J.1    Active-Controlled2
  • 61
    • 0037472837 scopus 로고    scopus 로고
    • Non-inferiority trials: Design concepts and issues-The encounters of academic consultants in statistics
    • D'Agostino, R. B., Sr., Massaro, J. M. & Sullivan, L. M. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat. Med. 22, 169-186 (2003).
    • (2003) Stat. Med , vol.22 , pp. 169-186
    • D'Agostino Sr., R.B.1    Massaro, J.M.2    Sullivan, L.M.3
  • 62
    • 0034687076 scopus 로고    scopus 로고
    • Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases
    • Ellenberg, S. S. & Temple, R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann. Intern. Med. 133, 464-470 (2000).
    • (2000) Ann. Intern. Med , vol.133 , pp. 464-470
    • Ellenberg, S.S.1    Temple, R.2
  • 63
    • 0041639486 scopus 로고    scopus 로고
    • Active-control clinical trials to establish equivalence or noninferiority: Methodological and statistical concepts linked to quality
    • Gomberg-Maitland, M., Frison, L. & Halperin, J. L. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. Am. Heart J. 146, 398-403 (2003).
    • (2003) Am. Heart J , vol.146 , pp. 398-403
    • Gomberg-Maitland, M.1    Frison, L.2    Halperin, J.L.3
  • 64
    • 33745931889 scopus 로고    scopus 로고
    • Good enough: A primer on the analysis and interpretation of noninferiority trials
    • Kaul, S. & Diamond, G. A. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann. Intern. Med. 145, 62-69 (2006).
    • (2006) Ann. Intern. Med , vol.145 , pp. 62-69
    • Kaul, S.1    Diamond, G.A.2
  • 65
    • 0034687072 scopus 로고    scopus 로고
    • Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues
    • Temple, R. & Ellenberg, S. S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann. Intern. Med. 133, 455-463 (2000).
    • (2000) Ann. Intern. Med , vol.133 , pp. 455-463
    • Temple, R.1    Ellenberg, S.S.2
  • 66
    • 0037285074 scopus 로고    scopus 로고
    • Statistical issues on objective, design, and analysis of noninferiority active-controlled clinical trial
    • Tsong, Y., Wang, S. J., Hung, H. M. & Cui, L. Statistical issues on objective, design, and analysis of noninferiority active-controlled clinical trial. J. Biopharm. Stat. 13, 29-41 (2003).
    • (2003) J. Biopharm. Stat , vol.13 , pp. 29-41
    • Tsong, Y.1    Wang, S.J.2    Hung, H.M.3    Cui, L.4
  • 67
    • 78249278823 scopus 로고    scopus 로고
    • Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designs
    • Ruperto, N. et al. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. Arthritis Rheum. 62, 3131-3139 (2010).
    • (2010) Arthritis Rheum , vol.62 , pp. 3131-3139
    • Ruperto, N.1
  • 68
    • 51749123391 scopus 로고    scopus 로고
    • Speeding up the evaluation of new agents in cancer
    • Parmar, M. K. et al. Speeding up the evaluation of new agents in cancer. J. Natl Cancer Inst. 100, 1204-1214 (2008).
    • (2008) J. Natl Cancer Inst , vol.100 , pp. 1204-1214
    • Parmar, M.K.1
  • 69
    • 33746551430 scopus 로고    scopus 로고
    • FDA
    • FDA. Critical Path Opportunities Report [online], http://www.fda.gov/ downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/UCM077254.pdf (2006).
    • (2006) Critical Path Opportunities Report
  • 70
    • 78249249606 scopus 로고    scopus 로고
    • Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group
    • Gallo, P. et al. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group. J. Biopharm. Stat. 20, 1115-1124 (2010).
    • (2010) J. Biopharm. Stat , vol.20 , pp. 1115-1124
    • Gallo, P.1
  • 71
    • 0035100888 scopus 로고    scopus 로고
    • Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
    • Biomarkers Definitions Working Group
    • Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharm. Ther. 69, 89-95 (2001).
    • (2001) Clin. Pharm. Ther , vol.69 , pp. 89-95
  • 72
    • 84863709923 scopus 로고    scopus 로고
    • Incorporating biomarkers into clinical trial designs: Points to consider
    • Bradley, E. Incorporating biomarkers into clinical trial designs: points to consider. Nat. Biotechnol. 30, 596-599 (2012).
    • (2012) Nat. Biotechnol , vol.30 , pp. 596-599
    • Bradley, E.1
  • 73
    • 79957857433 scopus 로고    scopus 로고
    • The BATTLE trial: Personalizing therapy for lung cancer
    • Kim, E. S. et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 1, 44-53 (2011).
    • (2011) Cancer Discov , vol.1 , pp. 44-53
    • Kim, E.S.1
  • 75
    • 58149151278 scopus 로고    scopus 로고
    • The use of genomics in clinical trial design
    • Simon, R. The use of genomics in clinical trial design. Clin. Cancer Res. 14, 5984-5993 (2008).
    • (2008) Clin. Cancer Res , vol.14 , pp. 5984-5993
    • Simon, R.1
  • 76
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Onc. 26, 1626-1634 (2008).
    • (2008) J. Clin. Onc , vol.26 , pp. 1626-1634
    • Amado, R.G.1
  • 78
    • 8444239359 scopus 로고    scopus 로고
    • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
    • St Clair, E. W. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50, 3432-3443 (2004).
    • (2004) Arthritis Rheum , vol.50 , pp. 3432-3443
    • St Clair, E.W.1
  • 79
    • 54949137664 scopus 로고    scopus 로고
    • Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis
    • Bejarano, V. et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 59, 1467-1474 (2008).
    • (2008) Arthritis Rheum , vol.59 , pp. 1467-1474
    • Bejarano, V.1
  • 80
    • 48149100741 scopus 로고    scopus 로고
    • Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial
    • Emery, P. et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372, 375-382 (2008).
    • (2008) Lancet , vol.372 , pp. 375-382
    • Emery, P.1
  • 81
    • 67449124634 scopus 로고    scopus 로고
    • Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. A randomised controlled trial
    • Smolen, J. et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 68, 797-804 (2009).
    • (2009) Ann. Rheum. Dis , vol.68 , pp. 797-804
    • Smolen, J.1
  • 82
    • 84871093047 scopus 로고    scopus 로고
    • Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
    • Dougados, M. et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann. Rheum. Dis. 72, 43-50 (2012).
    • (2012) Ann. Rheum. Dis , vol.72 , pp. 43-50
    • Dougados, M.1
  • 83
    • 41849120516 scopus 로고    scopus 로고
    • Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
    • Genovese, M. C. et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann. Rheum. Dis. 67, 547-554 (2008).
    • (2008) Ann. Rheum. Dis , vol.67 , pp. 547-554
    • Genovese, M.C.1
  • 84
    • 67650379733 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
    • Smolen, J. S. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374, 210-226 (2009).
    • (2009) Lancet , vol.374 , pp. 210-226
    • Smolen, J.S.1
  • 86
    • 80052341629 scopus 로고    scopus 로고
    • The OMERACT ultrasound task force-status and perspectives
    • Naredo, E. et al. The OMERACT ultrasound task force-status and perspectives. J. Rheumatol. 38, 2063-2067 (2011).
    • (2011) J. Rheumatol , vol.38 , pp. 2063-2067
    • Naredo, E.1
  • 87
    • 80052050619 scopus 로고    scopus 로고
    • Development and preliminary validation of a magnetic resonance imaging joint space narrowing score for use in rheumatoid arthritis: Potential adjunct to the OMERACT RA MRI scoring system
    • Ostergaard, M. et al. Development and preliminary validation of a magnetic resonance imaging joint space narrowing score for use in rheumatoid arthritis: potential adjunct to the OMERACT RA MRI scoring system. J. Rheumatol. 38, 2045-2050 (2011).
    • (2011) J. Rheumatol , vol.38 , pp. 2045-2050
    • Ostergaard, M.1
  • 88
    • 80052320868 scopus 로고    scopus 로고
    • OMERACT 10 Sharp Symposium: Important findings in examination of imaging methods for measurement of joint damage in rheumatoid arthritis
    • Strand, V. et al. OMERACT 10 Sharp Symposium: important findings in examination of imaging methods for measurement of joint damage in rheumatoid arthritis. J. Rheumatol. 38, 2009-2013 (2011).
    • (2011) J. Rheumatol , vol.38 , pp. 2009-2013
    • Strand, V.1
  • 89
    • 84860390334 scopus 로고    scopus 로고
    • Predictive biomarkers: A paradigm shift towards personalized cancer medicine
    • La Thangue, N. B. & Kerr, D. J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Onc. 8, 587-596 (2011).
    • (2011) Nat. Rev. Clin. Onc , vol.8 , pp. 587-596
    • La Thangue, N.B.1    Kerr, D.J.2
  • 90
    • 84863475669 scopus 로고    scopus 로고
    • On the independence of data monitoring committee in adaptive design clinical trials
    • Chow, S.C., Corey, R. & Lin, M. On the independence of data monitoring committee in adaptive design clinical trials. J. Biopharm. Stat. 22, 853-867 (2012).
    • (2012) J. Biopharm. Stat , vol.22 , pp. 853-867
    • Chow, S.C.1    Corey, R.2    Lin, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.